Sarkisian Steven R

Prospective, Randomized, Controlled Pivotal Trial of an Ab Interno Implanted Trabecular Micro-Bypass in Primary Open-Angle Glaucoma and Cataract: Two-Year Results.

Clinically and statistically greater reductions in IOP without medication were achieved after iStent inject implantation with cataract surgery versus cataract surgery alone, with excellent safety through 2 years.

Effectiveness and Safety of iStent Infinite Trabecular Micro-Bypass for Uncontrolled Glaucoma.

iStent infinite stand-alone surgery achieved clinically significant IOP reduction and favorable safety in patients with OAG uncontrolled by prior therapy.

Phase 3 Randomized Clinical Trial of the Safety and Efficacy of Travoprost Intraocular Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension.

The travoprost intraocular implant demonstrated robust IOP reduction over the 3-month primary efficacy evaluation period after a single administration.

Phase 3, Randomized, Comparison Study of Intracameral Bimatoprost Implant 10 µg and Selective Laser Trabeculoplasty.

The bimatoprost implant demonstrated statistical and clinical noninferiority to SLT in IOP reduction from baseline at weeks 4, 12, and 24.

Visual outcomes of combined cataract surgery and minimally invasive glaucoma surgery.

Minimally invasive glaucoma surgery (MIGS) has become a reliable standard of care for the treatment of glaucoma when combined with cataract surgery.

Standalone interventional glaucoma: evolution from the combination-cataract paradigm.

This interventional mindset has been made possible by the increasing diversity and availability of effective minimally invasive treatment options.

Erratum to: Visual outcomes of combined cataract surgery and minimally invasive glaucoma surgery.

Cochrane Reviews Regarding Minimally Invasive Glaucoma Surgical Techniques-Validity of Conclusions May Be Limited by Incomplete Evidence.

Consultation Section: Glaucoma. July consultation #5.

Efficacy of selective laser trabeculoplasty after canaloplasty.

July consultation #5.